{"entity":{"id":"idea-reg-regulator-ready-repurposing-dossiers","kind":"idea","name":"Fund regulator-ready evidence dossiers for the 20 best-supported off-patent drugs","aka":[],"tldr":"The evidence for old drugs against cancer is scattered across hundreds of papers. Assembling it into the format regulators and funders need is cheap and would speed decisions.","summary":"The Anticancer Fund's ReDO_DB and similar efforts catalogue candidates but stop short of the structured, regulator-grade dossiers (preclinical summary, pharmacology, safety in the target population, systematic review of clinical signals, proposed trial design) that a funder or a third-party label filing needs. The proposal is a funded programme, with methodologists and regulatory writers, that produces and publishes open dossiers for the 20 candidates with the strongest evidence, updated annually, each ending with a prioritised trial proposal and a regulatory strategy.","asOf":"2026-09-08","links":[{"label":"ReDO_DB (page moved; nearest live section)","url":"https://www.anticancerfund.org/en/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-generic-repurposing","b-knowledge-diffusion"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Within three years, at least half of the dossiers lead to a funded trial or a regulatory or guideline submission, compared with a small minority of candidates in the current catalogue.","rationale":"Funders and regulators act on well-organised evidence; the marginal cost of a dossier is trivial against the cost of the trial it enables, and public dossiers prevent duplicated effort across countries.","test":"Produce the first ten dossiers, circulate to funders and regulators, and track downstream trial funding and submissions against ten matched candidates without dossiers.","maturity":"early-clinical","actor":"philanthropy","cost":"small","horizonYears":2},"route":"/ideas/idea-reg-regulator-ready-repurposing-dossiers/","neighbours":{"bottleneck":[{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/"},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/"}]}}